How long does it usually take to take Inalisate (Iheli) and the description of the treatment cycle

Inavolisib (Inavolisib) is an oral selective PI3Kα inhibitor, mainly used to treat patients with breast cancer and some solid tumors carrying PIK3CA mutations. Its mechanism of action is to block tumor cell proliferation and survival signals by inhibiting the PI3K α signaling pathway, thereby inhibiting tumor growth and inducing cell apoptosis. In clinical application, reasonable treatment courses and treatment cycles are of great significance to efficacy and safety.

Under normal circumstances, the course of taking inaliset is continuous oral administration once a day, and long-term maintenance treatment is carried out according to the doctor's recommendations until disease progression or intolerable adverse reactions occur. In clinical trials, most patients can observe a decrease in tumor marker levels or a shrinkage of lesions according to imaging evaluation after taking it for several weeks, but the length of the treatment course needs to be adjusted based on individual tumor response.

The treatment cycle is generally 28 days, that is, taking the medicine at the prescribed dose every day 28 days before the efficacy and safety evaluation, including imaging examinations, hematology monitoring and biochemical index testing. If the patient tolerates it well and the efficacy is obvious, the next cycle can be continued; if moderate or severe adverse reactions occur, the doctor may suspend the medication or adjust the dose according to the patient's condition, and then continue subsequent cycles.

In long-term application, the management of inaliside treatment courses and cycles needs to be individually adjusted based on the patient's tumor type, mutation status, previous treatment history and individual tolerance. Through regular monitoring and periodic evaluation, the risk of adverse events can be reduced while ensuring therapeutic efficacy, achieving long-term disease control and optimizing quality of life.

Reference link:https://www.drugs.com